Pall T. Onundarson: The FIIX Test Receives Attention and A Call for Further Study at the ISTH 2026
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared on LinkedIn:
”The FIIX Test received attention and a call for further study at the ISTH 2026 meeting.
Unfortunately, I couldn´t attend the meeting in Paris but I have listened to some replays, including the SSC meeting on VKA monitoring:
Emilie Belley-Côté, MD, PhD (McMaster University) said during her presentation (slightly paraphrased):
‘Vitamin K antagonists remain the only oral anticoagulants for certain conditions (MHV, RHD-AF, APLAS) but we need better ways to monitor VKA´s.
I´m very interested in this Fiix assay that monitors a specific FII and X normalized ratio (Fiix-NR) that is not dependent on the short acting factor VII that makes most of the INR variation. This test has only been studied sofar in Iceland and they have received very good results.
So this is something my group at McMaster is looking into studying in Canada and hopefully elsewhere as well in the future’
Steve Kitchen, PhD (Scientific Director of the UK National External Quality Assessment Scheme and the WHO International EQA Scheme for Blood Coagulation, Sheffield, UK) said during his presentation (also slightly paraphrased):
‘I think that the Fiix test is an attractive option for VKA monitoring that should be considered…and I think Mark Crowther and Karen Moffat at McMaster University [in fact also Emilie Belley-Côté, Daniel M. Witt and others] have some studies underway – perhaps you are involved?’
The improvement reported in the Fiix blinded randomized clinical trial (Onundarson PT et al., The Lancet Haematology, 2015) was achieved on top of all patients already receiving high-quality anticoagulation management using the DAWN OAC software.
According to Dr. Kitchen, an estimated 90 million people worldwide remain on VKAs.
Don´t they deserve the best monitoring available?
If monitoring can be improved, shouldn´t the medical community pursue it?”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question